Gıancarlo Comı

Research interests

Publications

• Locus for severity implicates CNS resilience in progression of multiple sclerosis

  Nature · 2023 · https://doi.org/10.1038/s41586-023-06250-x

• Multiple sclerosis progression: time for a new mechanism-driven framework

  The Lancet Neurology · 2022 · https://doi.org/10.1016/s1474-4422(22)00289-7

• Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

  Annals of Neurology · 2021 · 10.1002/ana.26028

• Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

  The Lancet Neurology · 2021 · https://doi.org/10.1016/s1474-4422(21)00301-x

• Ofatumumab versus Teriflunomide in Multiple Sclerosis

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1917246

• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30238-8

• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30239-x

• Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

  Science · 2019 · https://doi.org/10.1126/science.aav7188

• ECTRIMS / EAN guideline on the pharmacological treatment of people with multiple sclerosis

  European Journal of Neurology · 2018 · https://doi.org/10.1111/ene.13536

• ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

  Multiple Sclerosis Journal · 2018 · https://doi.org/10.1177/1352458517751049

• Typical and atypical pathology in primary progressive aphasia variants

  Annals of Neurology · 2017 · https://doi.org/10.1002/ana.24885

• Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1601277

• Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Neurology · 2014 · 10.1016/s1474-4422(13)70308-9

• Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

  Nature Genetics · 2013 · 10.1038/ng.2770

• Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1104318

• Treatment of cognitive impairment in multiple sclerosis: position paper

  Journal of Neurology · 2012 · https://doi.org/10.1007/s00415-012-6678-0

• Association between pathological and MRI findings in multiple sclerosis

  The Lancet Neurology · 2012 · https://doi.org/10.1016/s1474-4422(12)70003-0

• Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2011 · 10.1056/nejmoa1014656

• Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

  Nature · 2011 · 10.1038/nature10251

• Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2010 · 10.1056/nejmoa0907839

• A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2010 · 10.1056/nejmoa0902533

• Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms

  Brain · 2009 · 10.1093/brain/awp174

• Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

  The Lancet · 2009 · https://doi.org/10.1016/s0140-6736(09)61259-9

• 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

  The Lancet Neurology · 2009 · https://doi.org/10.1016/s1474-4422(09)70226-1

• Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis

  Journal of Neuroscience · 2009 · 10.1523/jneurosci.5804-08.2009

• Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical Outcome

  Stroke · 2008 · 10.1161/strokeaha.107.510321

• Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism

  Nature · 2005 · 10.1038/nature03889

• Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis

  Nature · 2003 · 10.1038/nature01552

• Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy

  Annals of Neurology · 2001 · 10.1002/ana.1088

• Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

  Nature Medicine · 2000 · https://doi.org/10.1038/80525

• Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis

  Annals of Neurology · 1998 · https://doi.org/10.1002/ana.410430616

• Retinopathy and Vision Loss in Insulin-dependent Diabetes in Europe

  Ophthalmology · 1997 · https://doi.org/10.1016/s0161-6420(97)30327-3

Current projects

No projects listed.